Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus [Seeking Alpha]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Seeking Alpha
Terry Chrisomalis Investing Group Leader Follow Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025. The global Lupus drugs market is expected to reach $4.2 billion by 2031. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Tempura/E+ via Getty Images Sana Biotechnology, Inc. NASDAQ: SANA ) is gearing up to have a major inflection point in 2025. This is the release of initial data from its phase 1 study using SC291 for the treatment of patients with This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central phar
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAPR Newswire
- Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus ErythematosusGlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANAAccesswire
SANA
Earnings
- 11/8/24 - Miss
SANA
Sec Filings
- 11/26/24 - Form 144
- 11/25/24 - Form 144
- 11/21/24 - Form 3/A
- SANA's page on the SEC website